| scholarly article | Q13442814 |
| P50 | author | Arul Chinnaiyan | Q4802034 |
| Martin Hirst | Q30421490 | ||
| Mark Rubin | Q37375521 | ||
| Francesca Demichelis | Q42532145 | ||
| Himisha Beltran | Q90576129 | ||
| Christopher A Maher | Q94483659 | ||
| Colin Collins | Q104143274 | ||
| P2093 | author name string | Ladan Fazli | |
| Martin Gleave | |||
| Yuwei Wang | |||
| Hui Xue | |||
| Peter W Gout | |||
| Marco Marra | |||
| Martin Lubin | |||
| Chunxiao Wu | |||
| Yuzhuo Wang | |||
| Joseph R Bertino | |||
| Hongwei Cheng | |||
| Sonal Brahmbhatt | |||
| Antonio Hurtado-Coll | |||
| Stanislav V Volik | |||
| Shawn Anderson | |||
| Robert H Bell | |||
| Anne Haegert | |||
| Anna V Lapuk | |||
| P2860 | cites work | Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor | Q24319189 |
| Mapping short DNA sequencing reads and calling variants using mapping quality scores | Q24644612 | ||
| Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma | Q24685552 | ||
| Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line | Q28215271 | ||
| Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution | Q29619477 | ||
| Integrative genomic profiling of human prostate cancer | Q29619905 | ||
| Brain metastasis from prostate small cell carcinoma: not to be neglected | Q30751480 | ||
| Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate | Q33343227 | ||
| Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy | Q33455616 | ||
| Neuroendocrine differentiation in prostatic carcinoma | Q33604393 | ||
| Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer | Q33730189 | ||
| Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications | Q34243006 | ||
| Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models | Q34266365 | ||
| Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. | Q34429946 | ||
| Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes | Q34544350 | ||
| Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5'-methylthioadenosine phosphorylase. | Q34575673 | ||
| Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer | Q34728470 | ||
| Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA). | Q34756307 | ||
| Small cell carcinoma of prostate: Effectiveness of hormonal versus chemotherapy | Q35227930 | ||
| The mighty mouse: genetically engineered mouse models in cancer drug development | Q36568461 | ||
| Advances in whole genome sequencing technology. | Q37807055 | ||
| Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: current strategies | Q37837359 | ||
| Diagnosing and treating small-cell carcinomas of prostatic origin | Q39411095 | ||
| Use of irinotecan for treatment of small cell carcinoma of the prostate | Q39643737 | ||
| Insulin receptor expression by human prostate cancers | Q39941083 | ||
| ASAP1, a gene at 8q24, is associated with prostate cancer metastasis | Q39976234 | ||
| A transition state analogue of 5'-methylthioadenosine phosphorylase induces apoptosis in head and neck cancers | Q40124146 | ||
| Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy | Q40267159 | ||
| An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. | Q40374898 | ||
| Small cell carcinoma of the bladder and prostate | Q40379901 | ||
| Development and characterization of efficient xenograft models for benign and malignant human prostate tissue | Q42473593 | ||
| CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival | Q43191497 | ||
| Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors | Q43249140 | ||
| A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer | Q46490111 | ||
| Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. | Q47740760 | ||
| Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts | Q64387019 | ||
| The CDKN2A tumor-suppressor locus--a tale of two proteins | Q74357703 | ||
| Progression of prostate cancer to neuroendocrine cell tumor | Q74507669 | ||
| Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract | Q74802832 | ||
| Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy | Q77651935 | ||
| Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models | Q81120942 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| patient | Q181600 | ||
| P304 | page(s) | 775-83 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target | |
| P478 | volume | 11 |
| Q33829767 | 6-thioguanine: a drug with unrealized potential for cancer therapy |
| Q36801631 | A case report and genetic characterization of a massive acinic cell carcinoma of the parotid with delayed distant metastases |
| Q38099732 | Cancer genome-sequencing study design |
| Q40656134 | Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas |
| Q39037597 | Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model |
| Q39354603 | From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer |
| Q21133782 | Functional identification of APIP as human mtnB, a key enzyme in the methionine salvage pathway |
| Q38457785 | GATA2 as a potential metastasis-driving gene in prostate cancer |
| Q90219942 | Genome-wide DNA copy number analysis and targeted transcriptional analysis of canine histiocytic malignancies identifies diagnostic signatures and highlights disruption of spindle assembly complex |
| Q37705596 | HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey |
| Q41830742 | Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer |
| Q39309476 | Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells |
| Q53775251 | Intracellular Elemental Patterns of Apoptosis Resistance in Transdifferentiated Androgen-Dependent Prostatic Carcinoma Cells. |
| Q38627406 | Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer |
| Q54289914 | Methylthioadenosine phosphorylase inactivation depends on gene deletion in laryngeal squamous cell carcinoma. |
| Q39673894 | Next generation patient-derived prostate cancer xenograft models |
| Q41902787 | Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification |
| Q88909656 | Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine |
| Q57105900 | Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer |
| Q38090427 | The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing |
| Q42220108 | Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era. |
Search more.